Stockreport

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF ARQ-252 is a Potent Topical Small Molecule Inhibitor of JAK1High Selectivity for JAK1 over JAK2JAK Inhibition a Biologically Validated Target for Treatment of Hand Eczem [Read more]